

## HMS-CSSA Career Path Program

对话“千人计划”创业人才

### **Speech topic:**

### **Setting up a biotech start-up company in China**

张佩琢 博士

董事长兼CEO, 苏州吉玛制药技术有限公司

When: **2pm-4pm, Saturday, Nov. 17, 2012**

Where: Dana-Farber Cancer Institute, **65 Jimmy Fund Way**  
(close to Binney St), **Smith Building, Rm 308**, Boston, MA 02115



张佩琢博士于1988年在北京医科大学获得药物化学博士学位，毕业后在中国医药研究开发中心工作。1991年，张佩琢获得英国皇家奖学金，赴伦敦大学国王学院攻读核酸化学博士，师从C. B. Reese教授。在跟随Reese教授五年多的时间里，张博士参与了新型核酸化学的研发，修饰核苷的研究，固相DNA/RNA合成的研究等。1996年，张博士加盟英国Cruachem公司，任高级核酸化学研究员，开发新产品，并进行各种定制合成研究工作。2002年，他回到中国与人合资成立了上海吉玛制药技术有限公司，并于2007年成立苏州吉玛基因药物科技有限公司，专注于小干扰RNA的生产。目前张博士是苏州吉玛基因药物科技有限公司的董事长兼CEO。2009年，张博士入选国家“千人计划”，成为苏州市在生物医药领域首位入选“千人计划”的创业人才。

Peter Zhang, Ph.D.

Chairman and CEO, Suzhou GenePharma Co. Ltd.

Dr. Peter Zhang graduated from Beijing Medical University in 1988 with a Ph.D. degree in Medicinal Chemistry. Following his studies, he worked for the National Pharmaceutical Institute of R&D in Beijing for two years. In 1991 he was awarded Royal Fellowship and joined Prof. C. B. Reese's group in King's College London to study nucleic acid chemistry. For more than five years in Prof. Reese's lab, he was involved in developing new RNA chemistry, modification of nucleosides for antisense study, and methodology study in solution and solid phase DNA/RNA synthesis. In 1996, Dr. Zhang joined Cruachem Ltd. in Scotland as Senior Nucleic Acid Chemist to develop new products, undertaking contract synthesis work. In 2002, he went back to China and co-founded Shanghai GenePharma Co. Ltd., and later co-founded Suzhou GenePharma Co. Ltd. in 2007, focusing on siRNA products. He presently serves as Chairman and CEO of the company. In 2009, Dr. Zhang was selected to the National Recruitment Program of Global Experts, and was the first one in the biomedical field at Suzhou.

## Sponsors



<http://www.invitrogen.com>

Life Technologies Corporation, a global biotechnology tools company dedicated to improving the human condition with innovative life science products



Abmart's goal is to enable every protein to have a standard set of monoclonal antibodies optimal for all possible applications